Mechanistically, tamoxifen treatment of breast cancers with wild-type ARID1A results in recruitment of HDAC1 to ARID1A-FOXA1-ER bound enhancers, resulting in decreased ER activity (Figure 1C). Here, ARID1A is linked to breast carcinoma.